New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma

被引：1
|
作者：
Naoun, Natacha [1 ]
Vano, Yann-Alexandre [2 ]
机构：
[1] Inst Cancerol Lorraine, Dept Oncol Med, F-54500 Vandoeuvre Les Nancy, France
[2] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris AP HP, Serv Oncol Med, Paris Ctr, F-75015 Paris, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 11期
关键词：
Advanced renal clear cell carcinoma; Vascular endothelial growth factor receptor tyrosine kinase; inhibitors (VEGFR TKIs); Anti-PD1; Therapeutic combination;
D O I：
10.1016/j.bulcan.2021.05.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：991 / 993
页数：4
相关论文
共 50 条
  • [1] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    [J]. FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
  • [2] Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma
    Anthony Markham
    [J]. Targeted Oncology, 2022, 17 : 193 - 201
  • [3] Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma
    Markham, Anthony
    [J]. TARGETED ONCOLOGY, 2022, 17 (02) : 193 - 201
  • [4] Advanced Renal Cell Carcinoma Cabozantinib plus Nivolumab: New First-Line Standard?
    Schmale, Ine
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 362 - 363
  • [5] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
  • [6] Advanced Renal Cell Carcinoma Cabozantinib plus Nivolumab becomes Treatment Option of the Future
    Schmale, Ine
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12)
  • [7] Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
    不详
    [J]. EUROPEAN UROLOGY, 2021, 80 (02) : 256 - 257
  • [8] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [9] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Gervaso, Lorenzo
    Fazio, Nicola
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 477
  • [10] Comparison of the Efficacy and Safety of Nivolumab Plus Cabozantinib versus Sunitinib in the Treatment of Elderly Patients with Advanced Clear Cell Renal Cell Carcinoma
    Liu, Yanjie
    Meng, Ying
    Li, Mengmeng
    Dong, Yanjiao
    [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2024, 77 (05): : 584 - 590
12345